Reboxetine in the treatment of bulimia nervosa:
a report of seven cases.

El-Giamal N, de Zwaan M, Bailer U, Lennkh C, Schussler P, Strnad A, Kasper S

Department of General Psychiatry,
University Hospital of Psychiatry,
Vienna, Austria
Int Clin Psychopharmacol 2000 Nov;15(6):351-6

ABSTRACT

Controlled trials in patients with bulimia nervosa have demonstrated efficacy of antidepressant medications with serotonergic function (e.g. fluoxetine) as well as noradrenergic function (e.g. desipramine). Seven outpatients with bulimia nervosa according to DSM-IV criteria were treated openly with 8 mg of reboxetine, a selective noradrenaline reuptake inhibitor (NRI) over a 12-week period. The patients were assessed with the Structured Clinical Interview for DSM, Clinical Global Impression, 17-item Hamilton Depression Rating scale (HAM-D), Eating Disorder Inventory, Eating Disorders Questionnaire, daily self-ratings of eating behaviour, and the UKU side-effect rating scale. Three patients dropped out prematurely, one after 6 weeks and two after 4 weeks of reboxetine treatment. The reasons for premature attrition were rapid remission in one patient after 2 weeks and constipation, which led to an increase in episodes of laxative intake in two patients. In the total group, the monthly binge eating frequency showed a reduction of 73% and the frequency of vomiting episodes per month decreased by 67%. Furthermore, there was a concomitant decrease of depression ratings (HAM-D: from 12.2-6.1). Reboxetine seems to be an option for the treatment of bulimia nervosa.

Back               to order (prescription not required)

                    Reboxetine  research / abstracts

         1.   Reboxetine  role in antidepressant therapy
         2.   Reboxetine  efficacy and tolerability
         3.   Reboxetine  clinical pharmacologic profile
         4.   Inhibiting  the reuptake of noradrenaline and serotonin
         5.   Reboxetine  and depression in the elderly
         6.   Reboxetine  with severe major depressive disorder
         7.   Reboxetine  clinical efficacy in major depression
         8.   Reboxetine  tolerability and safety for major depression
         9.   Reboxetine  comparison with fluoxetine
        10   Reboxetine  versus fluoxetine, impact on social functioning
        11.  Reboxetine  versus fluoxetine, differential effects
        12.  Reboxetine  prevents relapse in  major depression
        13   Reboxetine  efficacy compared with imipramine
        14.  Noradrenaline reuptake inhibition
        15.  Antidepressants  noradrenergic versus serotonergic 
        16.  Reboxetine  in the treatment of bulimia
        17.  Reboxetine  hemodynamic effects in healthy males
        18.  Reboxetine  effects of antidepressant therapy
        19.  Reboxetine  place in antidepressant therapy
        20.  Reboxetine  stimulant effects in patients with narcolepsy
        21.  Reboxetine  selective noradrenaline reuptake inhibitor (NARI)

       Reboxetine  manufacturer's product insert

                    HOME          to order (prescription not required)

 

 

Hit Counter